Cardinal Health Reports First Quarter Fiscal Year 2027 Results and Raises Outlook

Cardinal Health posts strong Q1 growth and raises full-year profit guidance.

What the company is saying

Cardinal Health reports first quarter fiscal 2027 revenue of $67.5 billion, up 5% year-over-year, and highlights a 13% increase in GAAP operating earnings to $753 million. The company emphasizes a 27% jump in GAAP diluted EPS to $2.38 and a 28% rise in non-GAAP diluted EPS to $3.26. CEO Jason Hollar frames the results as a demonstration of consistent execution and strategic focus, citing disciplined operations and portfolio strength. The company raises its fiscal 2027 non-GAAP EPS guidance to $12.80–$13.00, representing 17–19% growth from its FY26 ex-tariff refund baseline and 14–15% from reported FY26 results. Cardinal Health points to a completed $500 million share repurchase, a binding letter of intent to renew distribution agreements with CVS Health, and the expected Q3 FY27 closing of the AdaptHealth Diabetes Health business acquisition. The tone is confident, with management attributing profit gains in the Pharmaceutical and Specialty Solutions segment to brand and specialty product growth and positive generics performance, while acknowledging distribution and FX headwinds in the Global Medical Products and Distribution segment.

What the data suggests

The disclosed numbers show Cardinal Health delivering broad-based financial improvement in Q1 FY27. Revenue rose 5% to $67.5 billion, with GAAP operating earnings up 13% to $753 million and non-GAAP operating earnings up 17% to $1.0 billion. GAAP diluted EPS increased 27% to $2.38, and non-GAAP diluted EPS climbed 28% to $3.26, aided by a lower share count and reduced effective tax rate. Segment data reveal Pharmaceutical and Specialty Solutions revenue up 6% to $62.6 billion and profit up 17% to $783 million, driven by brand and specialty pharmaceutical sales and generics program strength. The Global Medical Products and Distribution segment saw flat revenue at $3.2 billion but a 28% profit decline to $33 million due to unfavorable distribution and FX impacts. The 'Other' segment posted 7% revenue growth to $1.8 billion and 16% profit growth to $193 million, with gains across Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics. Cash from operations was $1,398 million, and the company completed a $500 million share repurchase. The raised FY27 non-GAAP EPS guidance to $12.80–$13.00 reflects management's confidence in continued profit growth, with updated segment profit and revenue growth targets. The evidence supports management's positive narrative, with realised results matching or exceeding prior guidance.

Analysis

The announcement's tone is positive but proportionate to the substantial, realised financial progress disclosed. Cardinal Health reports strong year-over-year growth in revenue (+5%), GAAP operating earnings (+13%), and both GAAP and non-GAAP EPS (+27% and +28%, respectively), all supported by clear numerical data. Segment-level results are detailed, with Pharmaceutical and Specialty Solutions showing robust profit growth, and the 'Other' segment also improving. While the company raises forward-looking guidance for FY27 and references upcoming strategic actions (e.g., the AdaptHealth acquisition), the majority of key claims are realised and measurable. There is no evidence of narrative inflation or overstatement; forward-looking statements are clearly separated from realised results and are not exaggerated. Capital outlays (e.g., share repurchase) are already completed and do not rely on long-dated, uncertain returns. The data fully supports the positive narrative.

Risk flags

• ●Profitability in the Global Medical Products and Distribution segment declined 28% year-over-year to $33 million, reflecting ongoing margin pressure from distribution and foreign exchange impacts. Sustained underperformance in this segment could offset gains elsewhere if not addressed.
• ●The company's raised FY27 non-GAAP EPS guidance depends on continued strong execution in its Pharmaceutical and Specialty Solutions and 'Other' segments. Any disruption in brand or specialty pharmaceutical sales, generics program performance, or logistics operations could impact the ability to meet these targets.
• ●Execution risk remains around the anticipated Q3 FY27 closing of the AdaptHealth Diabetes Health business acquisition. Delays or integration challenges could affect the expected contribution to future growth.
• ●The company faces macro risks including regulatory changes affecting branded pharmaceutical pricing, potential supply disruptions linked to geopolitical events such as the conflict with Iran, and ongoing litigation exposure, including Department of Justice investigations.

Bottom line

Cardinal Health's Q1 FY27 results demonstrate strong operational and financial momentum, with revenue, earnings, and EPS all posting double-digit growth. The company is backing up its positive narrative with realised numbers and has responded by raising full-year non-GAAP EPS guidance to $12.80–$13.00. Segment performance is robust in pharmaceuticals and logistics, but the medical products segment remains a weak spot with declining profit. The completed $500 million share repurchase and additional $1.0 billion in credit facilities provide financial flexibility. While the outlook is positive, investors should monitor the integration of the pending AdaptHealth Diabetes Health business acquisition, margin recovery in medical products, and external risks such as regulatory and geopolitical factors. The most important takeaway is that Cardinal Health is delivering on its growth strategy and raising expectations for the remainder of the year, but execution risks remain, especially in underperforming segments and pending acquisitions.

Announcement summary

(NYSE:CAH) Cardinal Health reported first quarter fiscal year 2027 revenues of $67.5 billion, a 5% increase from $64.0 billion in the first quarter of fiscal year 2026. GAAP operating earnings for the quarter rose 13% to $753 million, while GAAP diluted earnings per share (EPS) increased 27% to $2.38. Non-GAAP operating earnings increased 17% to $1.0 billion, and non-GAAP diluted EPS rose 28% to $3.26. Net earnings attributable to Cardinal Health, Inc. were $554 million, up from $450 million, representing a 23% increase. Non-GAAP net earnings attributable to Cardinal Health, Inc. were $759 million, up from $611 million, a 24% increase. The effective tax rate for the quarter was 19.2%, compared to 24.1% in the prior year, and the non-GAAP effective tax rate was 18.5%, down from 21.9%. Cardinal Health completed a $500 million share repurchase program in the first quarter. In the Pharmaceutical and Specialty Solutions segment, first quarter revenue increased 6% to $62.6 billion, and segment profit increased 17% to $783 million, driven by brand and specialty pharmaceutical sales growth and positive generics program performance. The Global Medical Products and Distribution segment reported flat revenue at $3.2 billion, with segment profit decreasing 28% to $33 million due to unfavorable distribution and foreign exchange impacts. The 'Other' segment saw revenue increase 7% to $1.8 billion and profit rise 16% to $193 million, with growth across Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics. Cardinal Health raised its fiscal year 2027 non-GAAP EPS guidance to $12.80 to $13.00, representing 17% to 19% growth from its FY26 ex-tariff refund baseline and 14% to 15% growth from reported FY26 results. The company also raised its Pharmaceutical and Specialty Solutions profit growth guidance to 10% to 12%, 'Other' profit growth to 17% to 20%, and 'Other' revenue growth to 12% to 14%. The non-GAAP effective tax rate guidance was lowered to 18.5% to 19.5%, and diluted weighted average shares outstanding guidance was reduced to 231 million to 232 million, reflecting the timing of the $500 million accelerated share repurchase in Q1. Cardinal Health entered into a binding letter of intent to renew its pharmaceutical distribution agreements with CVS Health. The company anticipates completing the acquisition of AdaptHealth's Diabetes Health business in Q3 of fiscal 2027. Cardinal Health launched the INSIGHT-IBD real-world evidence study in partnership with Eli Lilly. The company announced an additional $1.0 billion in uncommitted revolving credit facilities. As of September 30, 2026, total assets were $59,544 million and total liabilities and shareholders' deficit were $59,544 million. Cash and equivalents at quarter end were $5,264 million. Net cash provided by operating activities in the first quarter was $1,398 million. Net cash used in investing activities was $251 million, and net cash used in financing activities included $500 million for the purchase of treasury shares.

Disagree with this article?